Enasidenib
AG-221-C-001
Phase 2 small_molecule completed
Quick answer
Enasidenib for Hematologic Neoplasms is a Phase 2 program (small_molecule) at AGIOS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AGIOS PHARMACEUTICALS, INC.
- Indication
- Hematologic Neoplasms
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed